Seres Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Seres Therapeutics

31/10/2023 18:32

* Seres Therapeutics Inc  MCRB.OQ   MCRB.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 45.8% decrease in revenue to $1.867 million from $3.44
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Seres Therapeutics
Inc is
for a loss of 50 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Seres
Therapeutics Inc is $11​, above​ its last closing price
of $1.45. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  0.53        0.53       0.36      Missed  -32.6
 Mar. 31 2023  -0.56       -0.55      -0.57     Missed  -3.8
 Dec. 31 2022  -0.30       -0.46      -0.54     Missed  -16.1​
 Sep. 30 2022  -0.50       -0.47      -0.49     Missed  -4.5
 ​​Jun.        -0.59       -0.60      -0.70     Missed  -17.4
 30 2022                                                
 Mar. 31 2022  -0.54       -0.52      -0.61     Missed  -16.4​
 Dec. 31 2021  -0.44       -0.44      -0.52     Missed  -19.1
 Sep. 30 2021  -0.48       -0.46      0.72      Beat    255.6
 This summary was machine generated October 31 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated